Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 9/20 | 0.62 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25891601 | 0.87 | ALDH1A1 (0.68) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5319286 | 0.86 | SMN1; SMN2 (0.71) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL8794400 | 0.85 | ALDH1A1 (0.69) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7420552 | 0.84 | MAPT (0.55) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL5039739 | 0.84 | LMNA (0.59) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL259406 | 0.84 | MAPT (0.69) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3738174 | 0.82 | GAA (1.00) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1110499 | 0.81 | GAA (0.69) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12582165 | 0.81 | GAA (0.69) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20598544 | 0.81 | GAA (0.69) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2666481-B9 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-2666481-B1 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-1712242-B1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA MASATOSHI (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| CN-101837125-B | Method of regulating phosphorylation of PTH protein and antiviral agents comprising SR protein activity regulator as the active ingredient | HAGIWARA MASATOSHI | 2014-02-26 | — | — | CN | disclosed |
| EP-2666481-A2 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA, Masatoshi (JP) | 2013-11-27 | — | — | EP | disclosed |
| CN-1921885-B | Use of an aniline derivative or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a viral infection in a patient | HAGIWARA MASATOSHI | 2013-06-12 | — | — | CN | disclosed |
| US-20130079369-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | Hagiwara, Masatoshi (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20100016359-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | MASATOSHI HAGIWARA | 2010-01-21 | — | — | US | disclosed |
| US-20100016359-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | MASATOSHI HAGIWARA | 2010-01-21 | — | — | US | disclosed |
| US-7569536-B2 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | Hagiwara, Masatoshi (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569536-B2 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | Hagiwara, Masatoshi (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569536-B2 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | Hagiwara, Masatoshi (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| CN-1921885-A | Method for controlling phosphorylation of SR protein and antiviral agent comprising SR protein activity controller as active ingredient | HAGIWARA MASATOSHI (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1712242-A1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA, Masatoshi (JP) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079369-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | SRPK1, SRPK3, SRPK2 | GAA 2208/4885MAPK1 617/4885LMNA 3518/4885 |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | SRPK1, SARS1, SRPK3 | GAA 4242/4885MAPK1 999/4885LMNA 4232/4885 |
| US-20100016359-A1 | METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY | SRPK1, SRPK3, SRPK2 | GAA 2208/4885MAPK1 617/4885LMNA 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.